Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
The positive findings come after the U.S. Food and Drug Administration previously shared concerns related to sterility assurance issues during the drug’s production.
“Becoming an independent department elevates this work and strengthens UCLA’s role in shaping the future of precision health," said the department's new acting chairman.
One of the tracer’s more significant advantages is its extended half-life of 109 minutes—significantly longer than other currently available PET MPI imaging agents.
The exam effectively helps providers manage patients’ treatment options, but for some, the costs associated with those treatments may negate the value of its findings.
By binding the substance to a radiotracer, experts were able to improve the accuracy of identifying these tumors by as much as 30% compared to the standard of care.
The newly approved radiotracer is seen as a major step forward for nuclear imaging technology. Specialists have been looking forward to its arrival on the market for quite some time.
Fibroblast activation protein inhibitor PET imaging may provide more accurate insight into the spread of pancreatic cancer than more commonly used 18F-FDG PET/CT.
The organization is teaming up with CereMark Pharma to conduct research on improving outcomes in soldiers and athletes with neurodegenerative conditions.
Reducing certain treatments by around 25% and 50% still achieves promising PSA response rates, but reduces some of the unwanted side effects of therapy, like dry mouth.